biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RockyBalboa who wrote (2386)	7/8/2009 12:49:42 PM
From: mlkr	Read Replies (1) of 3661

"Shares of Aryx Therapeutics were pummeled in premarket trading after the company announced that its trial comparing the experimental blood clotting drug tecarfarin failed to demonstrate superiority over warfarin, a standard treatment. The data was positive for both treatments. Tecarfarin stayed in its target therapeutic range 74 percent of the time while warfarin hit a nearly identical 73.2 percent mark. That's not what investors were looking for, though. Shares plunged 51 percent. Aryx CEO Paul Goddard said he plans to continue partnership talks after the company fully analyzes the numbers." source: biotech

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next